{"schema_version":"secwatch.filing_event.v1","accession":"0001178913-25-002515","form_type":"8-K","ticker":"SLXN","cik":"0002022416","company_name":"Silexion Therapeutics Corp","filed_at":"2025-07-29T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.836141+00:00","generated_at":"2026-05-17T23:49:34.094987+00:00","sec_items":["3.03","5.03","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Silexion Therapeutics effects 1-for-15 reverse stock split, adjusts warrant terms","bullets":["Reverse split effective after close July 28; trading on split-adjusted basis July 29 under same ticker SLXN.","Authorized shares unchanged at 1,481,482; par value increased from $0.0009 to $0.0135 per share.","Each warrant now exercisable for 1/15th of a share; exercise price adjusted to $1,552.50 per whole share.","No fractional shares will be issued; fractional interests rounded up to nearest whole share.","CUSIP for ordinary shares changed to G1281K 130; warrant CUSIP remains G1281K 114."],"urls":{"canonical":"https://secwatch.observer/filing/0001178913-25-002515","json":"https://secwatch.observer/filing/0001178913-25-002515.json","markdown":"https://secwatch.observer/filing/0001178913-25-002515.md","text":"https://secwatch.observer/filing/0001178913-25-002515.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2022416/000117891325002515/0001178913-25-002515-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2022416/000117891325002515/zk2533495.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T23:49:34.094987+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8b48a622805359f0cf03fe44177f290ba18fdcc1","claim":"Silexion Therapeutics Corp: Filed a certificate with the Cayman Islands Companies Registry to amend the Amended and Restated Memorandum of Association, effecting a 1-for-15 reverse share split. Authorized share capital remains $20,000 but now consists of 1,481,482 ordinary shares; par value increased from $0.0009 to $0.0135 pe (effective 2025-07-28).","evidence_excerpt":"On July 28, 2025, the Company’s Board of Directors, acting pursuant to that approval by the Company’s shareholders, effected the Reverse Share Split following the close of trading on the Nasdaq Capital Market through the filing of a certificate with the Companies Registry of the Cayman Islands that served as an effective amendment to the Company’s Amended and Restated Memorandum of Association (the “ Memorandum Amendment ”).","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/2022416/000117891325002515/0001178913-25-002515-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2025-07-28"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}